Insol-N - An Oral Ayurvedic Anti-diabetic with a difference

• INSOL-N is the drug of choice in keeping the blood sugar at normal level in 'Non insulin-dependent diabetes'.
• Also found useful in 'Insulin-dependent diabetes', as it reduces the daily requirement of insulin dosage.
• Does not cause hypogly caemic. It enhances the body lesistance (what of raises)
• Reduces the chances of possible complications of diabetes like Diabetic Gangrene, Diabetic Neuropathy, Diabetic Retinopathy and the Vascular disease like Atherosclerosis.

INSOL-N Tablet creates a new dimension in the treatment of DIABETES. Being a research product INSOL-N is a combination of more than forty anti-diabetic herbs, six 'bhasmas' and Shilajith. It keeps the blood sugar at normal level and due to the presence of various bhasmas, it raises the body resistance which is usually lowered in diabetics which in turn makes them less susceptible to other infections. INSOL-N is absolutely safe and there is no risk of hypoglycemic coma.

IMPORTANT BENEFITS OF INSOL-N THERAPY

• INSOL-N is the drug of choice in keeping the blood sugar at normal level in 'Non insulin-dependent diabetes'. Even in 'Insulin-dependent diabetes', INSOL-N is found useful as it reduces the daily requirement of insulin.

• Above all, the chances of possible complications of diabetes like Diabetic Gangrene, Diabetic Neuropathy, Diabetic Retinopathy and Vascular disease such as Atherosclerosis will be significantly reduced by regular usage of INSOL-N.

SCIENTIFIC BACKGROUND

INSOL-N Tablet, an oral Ayurvedic antidiabetic has undergone intensive research work. A post-graduate from Mangalore University in his research work induced diabetes or rats by injecting 'Alloxan' which destroys pancreas and subsequent administration of INSOL-N produced following results:

a) INSOL-N brings down the blood sugar to normal level within a short period.
b) Glycogen and protein levels in the tissues of the heart, liver and kidney are raised to normal level.
c) Lipid, cholesterol and tissue phosphates are brought down to normal level.
d) INSOL-N regenerates Beta cells of Islets of Langerhans of pancreas which secrete body Insulin. The researcher got his M.Phil for the above work.

Another post-graduate from Mangalore University is doing Ph.D on INSOL-N. An article was published in the souvenir released during the National Seminar on the role of Indigenous drug on diabetes mellitus held at Madras under the president ship of Dr.Sam G.P. Moses, Member, WHO Panel on Diabetes.

Diabetes Mellitus has been described in ancient Ayurvedic texts under the name 'Madhumeha'. They have also explained in-detail the etiology of the disease and various herbal remedies for the same. The Ayurvedic seers were aware of the genetic susceptibility and environmental factors responsible for the disease.

According to the modern science, Diabetes Mellitus is a clinical syndrome characterised by hyperglycemia due to absolute or relative deficiency of Insulin. Lack of Insulin affects the metabolism of carbohydrate, protein, fat, water and electrolytes. If this state persists for a long time, permanent and irreversible functional and structural changes in the cells of the body occur, leading to the so-called complications of diabetes which affect the eye, the kidney and the nervous system.

Ayurveda, which advocates a holistic approach to the disease and advices the treatment in totality, plays an important role in controlling the blood sugar level at normal and preventing the complications of diabetes mellitus.

Insol-N, an Ayurvedic medicine prepared by Muniyal Ayurvedic Research Centre, and tested on thousands of patients is one such medicine to treat Diabetes Mellitus and has clinically proved itself to rejuvenate the cells of Pancreas, hence helping the patient to live a healthy normal life.

Although diabetes is a disease with a very ancient history and has been extensively studied, it’s safe and truly satisfactory treatment continues to elude us. The incidence is increasing even in hither to less affected areas like developing countries and rural populations, where the prohibitive cost of currently followed treatment cannot be sustained. As a part of community health planning strategy, the search for locally available low cost medicine is on. As mentioned earlier there exist many scattered reports of orally used hypoglycemic drugs, based on both laboratory and clinical observations, but follow up is inadequate.

• Experiment 1: Experimental diabetes was induced by alloxan in albino rats. Insol–N, an ayurvedic drug, was used therapeutically to control hyperglycemia in the diabetic animals. Alloxan treated diabetic rats were studied for the effect of Insol-N on biochemical and histological aspects.
• Experiment 2: Oral administration of Insol-N normalised the elevated blood glucose levels of the diabetic rats after two and four weeks of therapy.

• Experiment 4: Glycogen and protein depletion observed in the diabetic rat tissue were reversed by Insol-N therapy.

Figures: Tissue Protein and Glycogen of normal and diabetic rats afetr Insol-N treatment.

• Experiment 5: Enhanced lipid and cholesterol levels in the diabetic state was found to be markedly reduced after treatment.

Figures: Tissue Lipids & Cholesterol of normal and diabetic rats after Insol-N treatment.

• Experiment 6: Pancreatic amylase activities were below normal in diabetic animals. Administration of Insol-N could elevate the enzyme levels, but not to normal levels.

Values given are mean + - SEM of seven animals in each group

*Variations are stastically significant at P<0.001

• Experiment 7: Enhanced levels of tissue phosphatase (acid and alkaline phosphatase ) and tissue transaminases (alanine and aspartate transaminases) in the diabetic tissues showed significant reduction after treatment.

• Experiment 8: Histological studies made in pancreas of diabetic rats showed islet cell degranulation and destruction of B cells. Regeneration of B-cells and increased islet cell mass was noted in the pancreas of diabetic rats after Insol-N treatment.

Normal Rats	Under Treatment	After Treatment

• In Non-Insulin Dependant Diabetes Mellitus
• As an adjuvant in IDDM along with Insulin therapy.
• Diabetic neuropathy.
• Diabetic nephropathy.